Key Investor Signals
Philips licence secures access to core sweat-sensing IP
DXcrete signed a 2026 licence with Philips covering sweat-sensing technology, including the electrowetting patent family used in BEA.
Peer-reviewed validation of core sweat-handling technology
A 2024 Lab on a Chip paper demonstrated on-body collection and transport of ~1 nL sweat droplets at resting sweat rates using wearable electrowetting.
€185,000 NWO Faculty of Impact funding secured
NWO Faculty of Impact awarded €185,000 to commercialise Emma Moonen’s sweat-sensing research, providing non-dilutive funding to move the technology toward a company product.
Other Positive Signals
- Received Metropoolregio Eindhoven support with LouwersHanique to begin pilot production of precision glass components for BEA.
- CrossRoads Vlaanderen-Nederland backed DXcrete to extend its low-sweat sensing platform into continuous lactate monitoring.
- Secured funding from Brabant Startup Fund to advance development of its BEA kidney-monitoring platform.
Team
Emma Moonen
Co-founder & CEO
- Cum laude PhD in Mechanical Engineering from TU/e, where she developed the sweat-sensing platform behind DXcrete.
- Lead author of the 2024 Lab on a Chip paper demonstrating wearable electrowetting for on-body sweat handling.
- Researched flexible transparent electrodes at the University of Cambridge Bioelectronics Laboratory.
Timon Grob
Co-founder & CPO
- Spent 24 years at Philips across medical wearables, connected sensing and healthcare interoperability.
- Product owner in Philips’ Connected Sensing Venture, covering wearable monitors including Healthdot.
- Led a Philips Research healthcare-interoperability programme and a 10-person specialist team.
Product
DXcrete is building BEA, a skin-worn patch that measures creatinine from trace sweat to support more frequent kidney-function monitoring outside the clinic. The system actively moves tiny sweat droplets to an on-chip sensor, allowing measurements while the wearer is at rest.
Handles sweat at resting rates
BEA collects sweat from individual glands and uses electrowetting to move ~1 nL droplets across an electrode array, so the platform can operate with the very low sweat volumes produced at rest.
Measures creatinine on-chip
The disposable microfluidic chip routes sweat droplets to a sensor designed to measure creatinine, a standard biomarker used to assess kidney filtration.
Skin-worn format for repeated monitoring
BEA combines the sweat-handling chip, creatinine sensor and electronics in a small patch designed to collect and digitise readings outside a laboratory workflow.
Market Overview
Chronic kidney disease can progress for years without obvious symptoms. Kidney function is followed using blood creatinine and urine protein tests, so clinicians see isolated measurements rather than a continuous trend and deterioration can be difficult to spot between routine checks.
The commercial opportunity is higher-frequency monitoring for patients at risk of progression. Today that means repeated sampling and laboratory analysis; a reliable skin-worn creatinine sensor could shift part of that monitoring into the home while keeping the measurement tied to a biomarker already used in care.
More than 10% of people in the Netherlands have chronic kidney damage.
Dialysis is among the most expensive treatments covered by Dutch basic health insurance, costing €80,000 to €120,000 per patient each year.
Grand View Research values the 2025 kidney function tests market at $1.1B, covering blood, urine and clearance testing.
Symptoms often appear only after kidney function falls to about 30%, so deterioration can remain unnoticed until late.
Comparable Outcomes
Itamar Medical
Itamar Medical developed WatchPAT, a device for diagnosing sleep apnea at home. It moved sleep testing outside specialist laboratories and made it easier to access. The company provides a precedent for building strategic value in accessible sleep medicine. ZOLL Medical acquired Itamar Medical in 2021 in a transaction valued at approximately $538 million.
Preventice Solutions
Preventice Solutions developed the BodyGuardian family of wearable cardiac monitors, combining ambulatory sensors with a cloud platform and diagnostic service that turned continuous data into clinical reports for physicians. Boston Scientific acquired Preventice in 2021 for $925 million upfront, with up to $300 million in commercial milestone payments. Preventice generated $158 million in net sales in 2020.
Interested in More Startups Like DXcrete?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.